The Axxia Platform:

  • Maintains the drug concentration within the therapeutic window
  • Avoids toxic CRS materials, degradants or leachants
  • Easily detected and removed if necessary for cessation of therapy or at the end of the life of the implant
  • Improves adherence by minimizing the number of doses
  • Should not succumb to sudden or unintended rapid release of the drug substance
  • Design of the device should mitigate the additive manufacturing cost
  • Enables the delivery of drugs which are rapidly cleared
  • Avoids discomfort during and after implantation

Disease classes for which the Axxia implant is expected to meet the above requirements, as well as promote patient compliance and be therapeutically and cost effective are:

  • Addiction treatment – drug addiction rehabilitation
  • CNS conditions (Bi-polar disorder, schizophrenia, epilepsy, Alzheimer’s disease etc.)
  • Diabetes and other chronic conditions
  • Infection
  • Pain in both human and veterinary settings
  • Oncology